for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Alimera Sciences Inc

ALIM.OQ

Latest Trade

5.10USD

Change

0.00(0.00%)

Volume

44,053

Today's Range

5.01

 - 

5.41

52 Week Range

0.00

 - 

18.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Alimera Sciences Reports Q3 Loss Per Share Of $0.04

Oct 29 (Reuters) - Alimera Sciences Inc <ALIM.O>::ALIMERA SCIENCES ANNOUNCES THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.04.Q3 REVENUE $12.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $12.8 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.04 -- REFINITIV IBES DATA.

Alimera Sciences Inc Enters Purchase Agreement With Lincoln Park Capital Fund To Purchase Up To $20.0 Million Of Shares Of Co's Common Stock

Oct 25 (Reuters) - Alimera Sciences Inc <ALIM.O>::ALIMERA SCIENCES INC - ENTERED INTO A PURCHASE AGREEMENT WITH LINCOLN PARK CAPITAL FUND TO PURCHASE UP TO $20.0 MILLION OF SHARES OF CO'S COMMON STOCK.

Alimera Sciences Announces Top Line Revenue Expectation For The Third Quarter Of 2019

Oct 2 (Reuters) - Alimera Sciences Inc <ALIM.O>::ALIMERA SCIENCES ANNOUNCES TOP LINE REVENUE EXPECTATION FOR THE THIRD QUARTER OF 2019.EXPECTS TO REPORT CONSOLIDATED NET REVENUE FOR Q3 OF 2019 EXCEEDING $12.8 MILLION.IN U.S. IN Q3, SAW SEQUENTIAL GROWTH OVER Q2.Q3 REVENUE VIEW $12.9 MILLION -- REFINITIV IBES DATA.

Alimera Sciences Board Of Directors Approves Reverse Stock Split And 10B5-1 Stock Purchase Plan For U.S. Executive Management

Sept 5 (Reuters) - Alimera Sciences Inc <ALIM.O>::ALIMERA SCIENCES BOARD OF DIRECTORS APPROVES REVERSE STOCK SPLIT AND 10B5-1 STOCK PURCHASE PLAN FOR U.S. EXECUTIVE MANAGEMENT.ALIMERA SCIENCES INC - CO'S BOARD, ITS COMPENSATION COMMITTEE HAVE APPROVED 10B5-1 STOCK PURCHASE PLANS FOR ALIMERA'S U.S. EXECUTIVE MANAGEMENT TEAM.ALIMERA SCIENCES INC - INTENDS TO EFFECT REVERSE STOCK SPLIT AS SOON AS PRACTICABLE.

Alimera Sciences Announces Second Quarter loss per share of $0.07

July 29 (Reuters) - Alimera Sciences Inc <ALIM.O>::ALIMERA SCIENCES ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 GAAP LOSS PER SHARE $0.07.Q2 REVENUE $10.9 MILLION VERSUS REFINITIV IBES ESTIMATE OF $13 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.04 -- REFINITIV IBES DATA.

Alimera Sciences Says Iluvien Expected To Launch In Certain EU Countries During Second Half Of 2019

June 6 (Reuters) - Alimera Sciences Inc <ALIM.O>::THREE-YEAR CLINICAL TRIAL RESULTS SUPPORT ILUVIEN® LAUNCH IN EUROPE FOR THE PREVENTION OF RELAPSE IN RECURRENT NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT.ALIMERA SCIENCES INC - ILUVIEN IS EXPECTED TO LAUNCH IN CERTAIN EU COUNTRIES DURING SECOND HALF OF 2019.ALIMERA SCIENCES INC - SINGLE ILUVIEN IMPLANT SIGNIFICANTLY DELAYED RECURRENCE AND REDUCED UVEITIS SYMPTOMS UPON RECURRENCE VERSUS ACTIVE CONTROL ARM.ALIMERA SCIENCES INC - IOP WAS WELL-CONTROLLED IN BOTH ARMS.

Alimera Sciences Reports Q1 Results

April 29 (Reuters) - Alimera Sciences Inc <ALIM.O>::ALIMERA SCIENCES ANNOUNCES FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE OVERVIEW.Q1 GAAP LOSS PER SHARE $0.04.Q1 REVENUE ROSE 34 PERCENT TO $12.9 MILLION.ALIMERA SCIENCES - AS OF MARCH 31, 2019, HAD CASH, CASH EQUIVALENTS OF ABOUT $13.1 MILLION VERSUS $13.0 MILLION IN CASH, CASH EQUIVALENTS REPORTED ON DEC 31, 2018.

Alimera Sciences Sees 2018 GAAP Net Revenue In Excess Of $45 Million And Q4 2018 GAAP Net Revenue In Excess Of $13 Million

Jan 7 (Reuters) - Alimera Sciences Inc <ALIM.O>::ALIMERA SCIENCES INC -SEES 2018 GAAP NET REVENUE IN EXCESS OF $45 MILLION AND Q4 2018 GAAP NET REVENUE IN EXCESS OF $13 MILLION - SEC FILING.

Alimera Sciences Says CEO Dan Myers To Retire

Nov 29 (Reuters) - Alimera Sciences Inc <ALIM.O>::SAYS CEO DAN MYERS TO RETIRE.C. DANIEL MYERS CO'S CEO, WILL RETIRE AS CHIEF EXECUTIVE OFFICER.J. PHILIP JONES, CURRENTLY THE COMPANY’S VICE PRESIDENT OF FINANCE, WILL BE PROMOTED TO THE ROLE OF CHIEF FINANCIAL OFFICER.JAMES R. LARGENT WILL STEP DOWN AS CHAIRMAN OF BOARD AND BECOME LEAD INDEPENDENT DIRECTOR.ALIMERA SCIENCES - RICHARD S. EISWIRTH, JR., CURRENTLY PRESIDENT AND CFO, WILL BE PROMOTED TO CEO AND ASSUME DAY-TO-DAY LEADERSHIP OF COMPANY.AS PART OF THE SUCCESSION PLAN, THE BOARD ALSO INCREASED THE NUMBER OF DIRECTORS ON THE BOARD FROM EIGHT TO NINE.C. DANIEL MYERS WILL SERVE AS NON-EXECUTIVE CHAIRMAN OF BOARD & WILL BE A CONSULTANT TO CO.APPROVED A SUCCESSION PLAN THAT WILL GENERALLY TAKE EFFECT ON JANUARY 2, 2019 - SEC FILING.

Alimera Sciences Q2 Loss Per Share $0.06

July 30 (Reuters) - Alimera Sciences Inc <ALIM.O>::ALIMERA SCIENCES REPORTS SECOND QUARTER 2018 RESULTS.Q2 LOSS PER SHARE $0.06.Q2 REVENUE ROSE 5 PERCENT TO $10.9 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.06, REVENUE VIEW $10.8 MILLION -- THOMSON REUTERS I/B/E/S.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up